Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404166 | 1.00 | MEN1 (0.38) | MEN1POLBKMT2AUTS2RPTGS2 | |
| SCHEMBL976313 | 0.89 | HPGDS (0.37) | MEN1POLBKMT2AUTS2RF2 | |
| SCHEMBL3401743 | 0.88 | BACE1 (0.37) | F2BACE2 | |
| SCHEMBL3408843 | 0.87 | UTS2R (0.39) | UTS2RF2DDR1 | |
| SCHEMBL3406266 | 0.87 | UTS2R (0.39) | UTS2RF2DDR1 | |
| SCHEMBL3401770 | 0.86 | CTSD (0.39) | UTS2RBACE2 | |
| SCHEMBL977235 | 0.86 | SLC6A9 (0.36) | KMT2AUTS2RF2LMNAHTT | |
| SCHEMBL977322 | 0.85 | RORC (0.37) | MEN1KMT2AUTS2RLMNAALDH1A1 | |
| SCHEMBL3655265 | 0.84 | MEN1 (0.38) | MEN1POLBKMT2AF2DDR1 | |
| SCHEMBL977200 | 0.81 | CA1 (0.38) | UTS2RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | claimed |
| EP-2254862-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | claimed |
| WO-2009118473-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | claimed |
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| EP-2254862-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009118473-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | QDPR, NHERF1, GABRR1 | MEN1 254/4885POLB 3961/4885KMT2A 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.